INTRODUCTION {#ene14009-sec-0005}
============

Parkinson\'s disease (PD) is a progressive neurodegenerative disorder involving the loss of dopaminergic cells in the substantia nigra pars compacta (SNc) [1](#ene14009-bib-0001){ref-type="ref"}. Disease progression may be associated with a deterioration of motor function and increased anti‐parkinsonian drug dose, resulting in an increased burden of managing PD. Levodopa is the most effective drug for relieving motor disability in PD, but increasing levodopa dosage, a longer levodopa treatment period and lower age at onset of PD are related to motor fluctuations (MFs), including levodopa‐induced dyskinesia (LID) and wearing off [2](#ene14009-bib-0002){ref-type="ref"}, [3](#ene14009-bib-0003){ref-type="ref"}, [4](#ene14009-bib-0004){ref-type="ref"}. Thus, the occurrence of MFs in PD is associated with disease progression. Additionally, MFs are usually associated with worsening quality of life [5](#ene14009-bib-0005){ref-type="ref"}. Therefore, monitoring the progression of nigrostriatal neuronal degeneration is useful in the management of PD. Recent developments in imaging techniques have enabled detection of the progression of nigrostriatal neuronal degeneration. ^123^I‐N‐v‐fluoropropyl‐2b‐carbomethoxy 3b‐(4‐iodophenyl)nortropane (^123^I‐FP‐CIT) labeled dopamine transporters (DaTs) may reveal dopaminergic neuronal terminal degeneration by single photon emission computed tomography (DaT‐SPECT). It was previously reported that DaT‐SPECT can be used to assess dopaminergic terminal function, which may be related to the improvement of motor symptoms after levodopa administration [6](#ene14009-bib-0006){ref-type="ref"}.

Specific fast spin‐echo T1‐weighted magnetic resonance imaging (MRI) at 3 Tesla (neuromelanin MRI; NM‐MRI) can detect neuromelanin in dopaminergic neurons in the SNc [7](#ene14009-bib-0007){ref-type="ref"}, [8](#ene14009-bib-0008){ref-type="ref"}, [9](#ene14009-bib-0009){ref-type="ref"}, [10](#ene14009-bib-0010){ref-type="ref"}. Kuya *et al*. [8](#ene14009-bib-0008){ref-type="ref"} reported a significant correlation between the size of the NM‐positive SNc area (NM‐SNc) on NM‐MRI and the mean putaminal specific binding ratio (SBR) on DaT‐SPECT. Therefore, both neuroimaging tools might be useful for monitoring and evaluating dopaminergic neuronal degeneration.

Recently, it was reported that decreased NM‐SNc size on NM‐MRI correlates with the prevalence of MFs in idiopathic PD and PARK2 disease [9](#ene14009-bib-0009){ref-type="ref"}. In addition, Hong *et al*. [11](#ene14009-bib-0011){ref-type="ref"} reported that lower DaT activity on ^18^F‐FP‐CIT positron emission tomography (PET) might be a significant predictor of the development of LID. However, it is controversial whether striatal DaT imaging predicts the degeneration of nigral neurons in PD [12](#ene14009-bib-0012){ref-type="ref"}. Hence, it remains unclear whether NM‐MRI or DaT‐SPECT is more accurate for monitoring MFs in advanced PD. To answer this question, the correlation between the NM‐SNc by NM‐MRI and the SBR was investigated. Whether clinical features, DaT‐SPECT or NM‐MRI provides the most useful tool for diagnosing MFs in advanced PD was explored.

METHODS {#ene14009-sec-0006}
=======

Participants {#ene14009-sec-0007}
------------

Participants were 35 PD patients and 23 healthy age‐matched controls (Table [1](#ene14009-tbl-0001){ref-type="table"}). Data were prospectively collected between March 2014 and April 2015. All patients with PD met the Movement Disorders Society clinical diagnostic criteria for PD. NM‐MRI data were obtained from all participants. In addition, 23 PD patients underwent both NM‐MRI and DaT‐SPECT (Table [2](#ene14009-tbl-0002){ref-type="table"}). This study was approved by the Ethics Committee of Juntendo University Hospital. Written informed consent was obtained from all participants prior to the study. The details of the study population are described in Appendix [S1](#ene14009-sup-0002){ref-type="supplementary-material"}.

###### 

Participants' background

  Variables                                    All            PD                 Control            *P*
  -------------------------------------------- -------------- ------------------ ------------------ -------------------------------------------------
  Age (years)                                  59 ± 16        60 ± 13            59 ± 19            0.77[\*](#ene14009-note-0001){ref-type="fn"}
  Males, no. (%)                               34 (58)        23 (66)            11 (48)            0.28[\*\*](#ene14009-note-0001){ref-type="fn"}
  NM‐SNc (pixels)                              63 (42--101)   46 (22.3--79.7)    94.2 (62.1--112)   \<0.001[\*](#ene14009-note-0001){ref-type="fn"}
  SBR[a](#ene14009-note-0001){ref-type="fn"}   --             2.4 (1.69--3.15)   --                 --

NM‐SNc, neuromelanin‐positive substantia nigra pars compacta area; PD, Parkinson\'s disease; SBR, specific binding ratio.Data are expressed as mean ± SD, *n* (%) (age, males); median (interquartile range) (NM‐SNc, SBR). \*Mann--Whitney *U* test; \*\*chi‐squared test; ^a^23 PD patients who had undergone both DaT‐SPECT and NM‐MRI.
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###### 

Baseline characteristics of the participants

  Variables                  PD all (NM‐MRI only)   PD with MFs         PD without MFs     *P*
  -------------------------- ---------------------- ------------------- ------------------ ----------------------------------------------------
  Age (years)                60 ± 13                56 ± 11             64 ± 13            NS[\*\*](#ene14009-note-0002){ref-type="fn"}
  Males, no. (%)             23 (66)                8 (57)              15 (71)            NS[\*](#ene14009-note-0002){ref-type="fn"}
  Handedness, right (%)      35 (100)               14 (100)            21 (100)           NS[\*](#ene14009-note-0002){ref-type="fn"}
  LD (mg)                    413 ± 260              574 ± 200           308 ± 244          0.002[\*\*](#ene14009-note-0002){ref-type="fn"}
  LEDD (mg)                  743 ± 383              1046 ± 320          540 ± 271          \<0.001[\*\*](#ene14009-note-0002){ref-type="fn"}
  Disease duration (years)   7.56 ± 4.06            10.7 ± 3.21         5.57 ± 3.98        \<0.001[\*\*](#ene14009-note-0002){ref-type="fn"}
  H&Y stage                  2.09 ± 1.20            2.58 ± 1.13         1.80 ± 1.03        0.016[\*\*](#ene14009-note-0002){ref-type="fn"}
  UPDRS III                  17.0 ± 11.3            25.0 ± 10.8         14.0 ± 9.73        0.004[\*\*](#ene14009-note-0002){ref-type="fn"}
  NM‐SNc (pixels)            46 (22.3--79.7)        20.0 (14.8--36.0)   65.5 (46.0--100)   \<0.0001[\*\*](#ene14009-note-0002){ref-type="fn"}
  Age at onset (years)       54.1 ± 14.4            45.9 ± 10.6         59.0 ± 14.2        0.004[\*\*](#ene14009-note-0002){ref-type="fn"}

  Variables                  PD (DaT‐SPECT and NM‐MRI)   PD with MFs         PD without MFs      *P*
  -------------------------- --------------------------- ------------------- ------------------- ----------------------------------------------------
  Age (years)                61 ± 16                     55 ± 11             66 ± 17             N.S.[\*\*](#ene14009-note-0002){ref-type="fn"}
  Males, no. (%)             14 (61)                     4 (40)              10 (76)             N.S.[\*](#ene14009-note-0002){ref-type="fn"}
  Handedness, right (%)      23 (100)                    10 (100)            13 (100)            N.S.[\*](#ene14009-note-0002){ref-type="fn"}
  LD (mg)                    432 ± 229                   535 ± 181           354 ± 238           0.04[\*\*](#ene14009-note-0002){ref-type="fn"}
  LEDD (mg)                  762 ± 329                   1009 ± 245          572 ± 252           \<0.001[\*\*](#ene14009-note-0002){ref-type="fn"}
  Disease duration (years)   8.39 ± 3.98                 10.5 ± 2.92         6.77 ± 4.02         0.02[\*\*](#ene14009-note-0002){ref-type="fn"}
  H&Y stage                  2.13 ± 1.22                 2.50 ± 1.08         1.84 ± 1.28         NS[\*\*](#ene14009-note-0002){ref-type="fn"}
  UPDRS III                  20.1 ± 12.6                 26.2 ± 11.5         15.3 ± 11.6         0.04[\*\*](#ene14009-note-0002){ref-type="fn"}
  NM‐SNc (pixels)            44 (19.8--61.6)             19.8 (15.1--35.6)   54.8 (45.5--91.1)   \<0.0001[\*\*](#ene14009-note-0002){ref-type="fn"}
  SBR                        2.4 (1.69--3.15)            1.98 (1.63--2.52)   2.84 (1.68--2.52)   NS[\*\*](#ene14009-note-0002){ref-type="fn"}
  Age at onset (years)       52.6 ± 16.0                 44.8 ± 9.93         58.61 ± 17.5        0.02[\*\*](#ene14009-note-0002){ref-type="fn"}

DaT‐SPECT, dopamine transporter single photon emission computed tomography; H&Y stage, Hoehn and Yahr stage; LD, levodopa daily dose; LEDD, levodopa equivalent daily dose; MFs, motor fluctuations; NM‐MRI, neuromelanin magnetic resonance imaging; NM‐SNc, neuromelanin‐positive substantia nigra pars compacta area; PD, Parkinson\'s disease; SBR, specific binding ratio; UPDRS III, Unified Parkinson\'s Disease Rating Scale part III.Data are expressed as mean ± SD, *n* (%) (age, male, handedness, affected side, LD, LEDD, disease duration, H&Y stage, UPDRS III; median (interquartile range) (NM‐SNc, SBR). \*Chi‐squared test; \*\*Mann--Whitney *U* test.
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Brain image protocol and analysis {#ene14009-sec-0008}
---------------------------------

The details of brain MRI protocol, image analysis and covariate assessment are described in Appendix [S1](#ene14009-sup-0002){ref-type="supplementary-material"}.

Statistical analysis {#ene14009-sec-0009}
--------------------

The details of the statistical analysis are described in Appendix [S1](#ene14009-sup-0002){ref-type="supplementary-material"}.

RESULTS {#ene14009-sec-0010}
=======

The clinical characteristics of the participants and the NM‐SNc and SBR results are shown in Tables [1](#ene14009-tbl-0001){ref-type="table"} and [2](#ene14009-tbl-0002){ref-type="table"}. Hyperintense areas determined by an individual background threshold (+2 SD) in all cases were found to be well distributed in the SNc.

There was no difference between PD patients and controls in the relative variation of background signals, ruling out significant differences in image quality \[median relative variation in background signal (interquartile range): PD, 18.2% (17.4%--20.0%); controls, 19.4% (17.1%--20.4%); Mann--Whitney *U* test, *P* = 0.59\]. The assessment of reproducibility of receiver operating characteristic (ROC) placements based on the SNc pixel counts between independent raters revealed strong agreement (intraclass correlation coefficient 0.94). NM‐MRI results showed a significantly smaller NM‐SNc in patients with PD than in controls (Table [1](#ene14009-tbl-0001){ref-type="table"} and Fig. [S1](#ene14009-sup-0001){ref-type="supplementary-material"}).

The NM‐SNc was significantly correlated with the SBR (*ρ* = 0.43, *P* \< 0.05; Fig. [1](#ene14009-fig-0001){ref-type="fig"}a). Age‐related effects were corrected by age matching between controls and PD patients. The NM‐SNc was significantly correlated with age in the normal group (*ρ *= 0.541, *P* \< 0.05). A similar age‐related correlation for NM‐related contrast was observed in the PD group (*ρ* = 0.278, *P* \< 0.05), whereas the SBR was not correlated with age (*ρ *= 0.069, *P* = 0.753). Furthermore, the correlation remained in the measurement of both the left and right hemispheres (right *ρ *= 0.42, *P* \< 0.05; left *ρ *= 0.49, *P* \< 0.05; Fig. [1](#ene14009-fig-0001){ref-type="fig"}b, c). In the advanced PD group, no significant correlation was found between the NM‐SNc and the SBR (*ρ *= 0.486, *P* = 0.329; Fig. [1](#ene14009-fig-0001){ref-type="fig"}d). This association was weakened further in the presence of severe deterioration of dopaminergic neurons in the affected side. The NM‐SNc and SBR were significantly smaller in the affected side than in the non‐affected side \[affected side, 75.0 (43.4--97.5) pixels, non‐affected side, 114 (80.0--138) pixels, *P* \< 0.05; affected side, 2.18 (1.70--3.01), non‐affected side, 2.85 (1.87--3.24), *P* \< 0.05, respectively\].

![Correlation between SNc area on NM‐MRI and SBR on DaT‐SPECT. (a) In 23 patients with PD, the size of NM‐SNc was associated with SBR on dopamine transporter imaging by DaT‐SPECT. (b), (c) The correlation was confirmed in both the right and left sides in 23 patients with PD. (d) Associations between NM‐SNc (pixel) on NM‐MRI and SBR on DaT‐SPECT of the severe PD group (six patients, Hoehn and Yahr 3 or higher). (a)--(d) Spearman\'s rank correlation test.](ENE-26-1408-g001){#ene14009-fig-0001}

The NM‐SNc was significantly negatively correlated with Unified Parkinson\'s Disease Rating Scale part III (UPDRS III) scores (*ρ *= 0.42, *P* \< 0.05; Fig. [2](#ene14009-fig-0002){ref-type="fig"}a), disease duration (*ρ *=* −*0.35, *P* \< 0.05; Fig. [2](#ene14009-fig-0002){ref-type="fig"}b) and levodopa equivalent daily dose (LEDD) (*ρ *=* −*0.39, *P* \< 0.05; Fig. [2](#ene14009-fig-0002){ref-type="fig"}c) and positively correlated with age at onset (*ρ *= 0.37, *P* \< 0.05; Fig. [2](#ene14009-fig-0002){ref-type="fig"}d) whilst the SBR did not correlate with any (Fig. [2](#ene14009-fig-0002){ref-type="fig"}e--h).

![Correlation between the NM‐SNc size or SBR and UPDRS III score, disease duration, LEDD and age at onset. Correlation between the size of the NM‐SNc (pixels) on NM‐MRI or SBR on DaT‐SPECT and UPDRS III score (a), (e), disease duration (b), (f), LEDD (c), (g) and age at onset (d), (h). (a)--(d) In 35 patients with PD,NM‐SNc size was associated with UPDRS III score, with disease duration, with LEDD and with age at onset (e)--(h). (a)--(h) Spearman\'s rank correlation test.](ENE-26-1408-g002){#ene14009-fig-0002}

To investigate the correlation between imaging biomarkers and MFs, the 35 PD patients who underwent NM‐MRI were divided into two groups based on the presence of MFs. This cohort included 21 PD patients without MFs (Table [2](#ene14009-tbl-0002){ref-type="table"}). Additionally, the 23 patients who underwent both DaT‐SPECT and NM‐MRI were also divided into two groups based on the presence of MFs: 10 patients with MFs and 13 without (Table [2](#ene14009-tbl-0002){ref-type="table"}). The PD with MFs group showed a significantly smaller NM‐SNc compared with the PD without MFs group (Table [2](#ene14009-tbl-0002){ref-type="table"}, Fig. [3](#ene14009-fig-0003){ref-type="fig"}a, b). In contrast, the SBR did not significantly differ between the PD with and without MFs groups (Table [2](#ene14009-tbl-0002){ref-type="table"}, Fig. [3](#ene14009-fig-0003){ref-type="fig"}c). Disease duration was longer in the PD with MFs than without MFs group (Table [2](#ene14009-tbl-0002){ref-type="table"}). The levodopa daily dose (LD) and LEDD of the PD with MFs group were higher than those of the PD without MFs group (Table [2](#ene14009-tbl-0002){ref-type="table"}). UPDRS III scores were significantly different between the two groups (Table [2](#ene14009-tbl-0002){ref-type="table"}). Age at PD onset was lower in the PD with MFs than in the PD without MFs group (Table [2](#ene14009-tbl-0002){ref-type="table"}).

![Comparison of NM‐MRI or SBR between groups with and without MFs in PD. The size of the NM‐SNc (pixels) by NM‐MRI was compared between PD patients with MFs (*N* = 14) and those without MFs (*N* = 21). (a), (b) SNc area was significantly decreased in PD patients with MFs (Mann--Whitney *U* tests, PD with versus without MFs, \*\*\**P* \< 0.001). (c) No significant difference in SBR was found between PD patients with and without MFs (Mann--Whitney *U* tests, not significant). (d) ROC curve analysis was used to examine predictors of MF onset in 23 patients with PD. The AUC of the NM‐SNc size showed a significant difference of 0.89 (*P* \< 0.05) but no significant difference was found in the SBR. The cutoff value was 37.5 (pixels) using the Youden index (sensitivity 0.846, specificity 0.90). Data are expressed as median.](ENE-26-1408-g003){#ene14009-fig-0003}

Receiver operating characteristic curves were used to assess the association factors for MF occurrence amongst PD patients. The area under the ROC curve (AUC) of the NM‐SNc showed a significant difference of 0.89 (*P* \< 0.05) but no significant difference was found in the AUC of the SBR (Fig. [3](#ene14009-fig-0003){ref-type="fig"}d), indicating that the NM‐SNc might be a marker associated with MFs.

The multivariate Cox regression hazard model revealed that NM‐SNc is a significant association factor for MFs in advanced PD (Table [3](#ene14009-tbl-0003){ref-type="table"}).

###### 

Summary of the association factors of the time to motor fluctuation occurrence in 23 patients with Parkinson\'s disease

  Variables              HR     95% CI       *P*
  ---------------------- ------ ------------ -------
  NM‐SNc (pixel)         0.94   0.88--0.99   0.04
  UPDRS III score        1.07   0.97--1.18   0.140
  SBR (%)                2.74   0.34--21.7   0.339
  LD (mg)                1.00   0.99--1.01   0.176
  Female                 5.55   0.53--57.5   0.151
  Age at onset (years)   0.96   0.84--1.09   0.510

CI, confidence interval; HR, hazard ratio; LD, levodopa daily dose; NM‐SNc, neuromelanin‐positive substantia nigra pars compacta area; SBR, specific binding ratio; UPDRS III, Unified Parkinson\'s Disease Rating Scale part III.
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DISCUSSION {#ene14009-sec-0011}
==========

The current results revealed that the NM‐SNc was significantly smaller in PD patients compared with healthy controls and was correlated with the SBR. DaT‐SPECT reflects dopaminergic neuronal axon terminal function in the putamen, whereas NM‐MRI directly visualizes melanin in the SNc. Sasaki *et al*. [13](#ene14009-bib-0013){ref-type="ref"} reported that the paramagnetic T1 shortening area in NM‐MRI was clearly correlated with NM‐SNc in gross specimens, suggesting that the high signal intensity areas corresponded to NM‐containing neurons [8](#ene14009-bib-0008){ref-type="ref"}, [13](#ene14009-bib-0013){ref-type="ref"}, [14](#ene14009-bib-0014){ref-type="ref"}. Colloby *et al*. [15](#ene14009-bib-0015){ref-type="ref"} reported that striatal ^123^I‐FP‐CIT uptake was significantly correlated with the number of NM‐containing neurons in the SNc. Previous neuropathological studies reported an association between the number of surviving NM‐containing neurons and the functional state of those neurons' axon terminals [16](#ene14009-bib-0016){ref-type="ref"}, [17](#ene14009-bib-0017){ref-type="ref"}. Therefore, NM‐SNc may predict not only the number of dopaminergic neurons but also the terminal function [8](#ene14009-bib-0008){ref-type="ref"}. Furthermore, PD pathology occurs asymmetrically and motor symptoms manifest unilaterally. Here, it is demonstrated that both NM‐SNc and SBR lateralization were correlated with clinical symptoms, similar to a previous report [8](#ene14009-bib-0008){ref-type="ref"}. Thus, both imaging biomarkers can predict impairment of the nigrostriatal pathway due to dopaminergic neuronal degeneration.

However, no correlation was found between the NM‐SNc and SBR in the advanced PD group in the current study (Fig. [1](#ene14009-fig-0001){ref-type="fig"}d). Investigation of postmortem SNc neuron counts in PD revealed that DaT‐SPECT fails to reflect the precise number of dopaminergic neurons [12](#ene14009-bib-0012){ref-type="ref"}. The SBR in PD might be associated with dysfunction of axon terminals rather than degeneration of dopaminergic neurons in the SNc. Reductions in DaT are observed from the early stages of the disease. Therefore, the SBR might decrease more than dopaminergic neuronal degeneration [18](#ene14009-bib-0018){ref-type="ref"}, whereas the loss of melanized neurons lags behind the loss of tyrosine‐positive neurons [17](#ene14009-bib-0017){ref-type="ref"}. Thus, decreasing melanin reflects the progression of dopaminergic neuronal degeneration. In advanced PD, although the SBR might not be closely related to dopaminergic neuronal degeneration, NM‐MRI can detect the melanized structures, resulting from precisely depicting the progression of dopaminergic neuronal degeneration. In the current study, no correlation was found between the SBR and UPDRS III scores (Fig. [2](#ene14009-fig-0002){ref-type="fig"}e), whereas the NM‐SNc was significantly negatively correlated with UPDRS III scores (Fig. [2](#ene14009-fig-0002){ref-type="fig"}a). In this context, DaT‐SPECT appears to be more useful for early PD diagnosis, whereas NM‐MRI might be useful for determining dopaminergic neuronal degeneration in advanced PD. The SBR decreased in early PD patients with no correlation with disease duration (Fig. [2](#ene14009-fig-0002){ref-type="fig"}f), whereas the NM‐SNc was significantly negatively correlated with disease duration (Fig. [2](#ene14009-fig-0002){ref-type="fig"}b).

Common risk factors for MFs, such as younger age of onset and long disease duration [2](#ene14009-bib-0002){ref-type="ref"}, [3](#ene14009-bib-0003){ref-type="ref"}, [4](#ene14009-bib-0004){ref-type="ref"}, [5](#ene14009-bib-0005){ref-type="ref"}, were identified in our cohort of patients. NM‐SNc size was correlated with longer disease duration consequent to early age at onset and dopaminergic drug dose, reflecting the status of advanced PD. Therefore, NM‐MRI may be a more accurate marker for discriminating the advanced status of PD than DaT‐SPECT. Cilia *et al*. [19](#ene14009-bib-0019){ref-type="ref"} investigated a large‐scale cohort of PD patients in Ghana and reported that MFs were associated with a long disease duration and high daily LD, similar to the current results. Previous studies reported that MFs might be correlated with presynaptic changes due to severe degeneration of dopaminergic neurons [11](#ene14009-bib-0011){ref-type="ref"}, [20](#ene14009-bib-0020){ref-type="ref"}. Presynaptic degeneration may induce abnormal fluctuation of postsynaptic dopaminergic stimulation under levodopa treatment, resulting in MFs [21](#ene14009-bib-0021){ref-type="ref"}. Considering the smaller NM‐SNc in PD with MFs than in PD without MFs (Fig. [3](#ene14009-fig-0003){ref-type="fig"}a, b), NM‐SNc might be correlated with MFs in advanced PD.

In the current study, however, no significant differences in the SBR between PD patients with and without MFs were found (Fig. [3](#ene14009-fig-0003){ref-type="fig"}c). Hong *et al*. [11](#ene14009-bib-0011){ref-type="ref"} reported that DaT SPECT was a predictive marker of LID. The researchers also found that younger age at onset of PD and higher levodopa dosages were related to the development of LID. Conversely, Roussakis *et al*. [22](#ene14009-bib-0022){ref-type="ref"} did not find any significant differences using DaT‐SPECT of ^123^I‐FP‐CIT binding to DaT between PD patients with and without LID. Considering the lack of correlation between striatal DaT binding and postmortem SNc neuron counts [12](#ene14009-bib-0012){ref-type="ref"}, the levels of SNc dopaminergic neuronal degeneration might not correlate with decreases in terminal DaT after a certain level of damage has occurred. Thus, DaT‐SPECT might not be as suitable for monitoring MFs in advanced PD as NM‐MRI.

The current study has several limitations that should be considered. First, the number of patients who underwent DaT‐SPECT was smaller than the number who underwent NM‐MRI. This may have affected the results such as the correlations between SBR and UPDRS III score or disease duration and might have led to different results compared with previous studies. Secondly, the PD with MFs group tended to be younger than those without MFs, but this difference was not significant. Younger age at onset of disease is a risk factor for MFs [2](#ene14009-bib-0002){ref-type="ref"}, [3](#ene14009-bib-0003){ref-type="ref"}, [4](#ene14009-bib-0004){ref-type="ref"}, [5](#ene14009-bib-0005){ref-type="ref"}; hence our results may have been influenced by participants' age. However, the model for predictive factors of the time to the occurrence of MFs revealed that NM‐SNc size was the most strongly associated factor (Table [3](#ene14009-tbl-0003){ref-type="table"}). Thirdly, the study cohort was relatively small and DaT‐SPECT was not performed on healthy controls. Fourthly, our patients were diagnosed clinically but did not undergo confirmation via autopsy. Fifthly, whilst this study had a cross‐sectional design, longitudinal studies are needed. Our results, however, concur with previous pathological analyses and clinical investigations of the association between MFs and SNc dopaminergic neuronal degeneration in advanced PD [19](#ene14009-bib-0019){ref-type="ref"}, [20](#ene14009-bib-0020){ref-type="ref"}.

CONCLUSION {#ene14009-sec-0012}
==========

Neuromelanin MRI appears to be useful for the assessment of dopaminergic neuron degeneration, whereas DaT‐SPECT might be more useful for predicting dysfunction rather than the degeneration of the nigrostriatal pathway in advanced PD. Importantly, reduction in NM‐SNc correlated with disease progression, suggesting that NM‐MRI is more accurate for monitoring MFs due to degeneration of dopaminergic neurons in advanced PD with longer disease duration consequent to early age at onset. Therefore, NM‐MRI might provide a better marker for discriminating advanced PD compared with DaT‐SPECT.

Supporting information
======================

###### 

**Figure S1.** NM‐MRI of controls and patients with PD.

###### 

Click here for additional data file.

###### 

**Appendix S1.** Methods

###### 

Click here for additional data file.
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